| Name | Title | Contact Details |
|---|
Jones Regional Medical Center is a Anamosa, IA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Uroplasty is a global medical company committed to offering transformative treatment options through specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Uroplasty’s products include the Urgent® PC Neuromodulation System, a non-drug, non-surgical office-based treatment for Overactive Bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Urgent PC is an FDA-cleared system that delivers PTNS (Percutaneous Tibial Nerve Stimulation) and is also indicated for the treatment of fecal incontinence outside the US market. Uroplasty also offers Macroplastique®, an injectable urethral bulking agent for female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Female SUI only in U.S.; male and female SUI outside the U.S. Uroplasty products are typically used when a patient’s treatment goals are not met after conservative and/or drug therapies. Providers and patients alike appreciate that Uroplasty products provide low-risk, effective alternatives to invasive surgery. And because these treatments can be delivered in an office or outpatient setting, the end result is that more patients are given the opportunity to transform their lives with successful treatment.
Share Medical Center is committed to the development of our staff.
Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.
Pet First Health Care is a Jeffersonville, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.